<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119444">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02036970</url>
  </required_header>
  <id_info>
    <org_study_id>RTA 402-C-1302</org_study_id>
    <nct_id>NCT02036970</nct_id>
  </id_info>
  <brief_title>Bardoxolone Methyl Evaluation in Patients With Pulmonary Arterial Hypertension (PAH)</brief_title>
  <acronym>PAH</acronym>
  <official_title>A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in
      patients with pulmonary arterial hypertension to determine the recommended dose range and
      evaluate the change from baseline in 6-minute walk distance (6MWD) following 16 weeks of
      study participation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The molecular and pharmacological effects of bardoxolone methyl are broad through its
      induction of Nrf2 and suppression of NF-κB. Bardoxolone methyl may therefore address
      multiple facets of the pathophysiology of PAH because it suppresses activation of
      proinflammatory mediators, enhances endothelial NO bioavailability, improves metabolic
      dysfunction, suppresses vascular proliferation, and prevents maladaptive remodeling.
      Furthermore, while existing therapies primarily target only smooth muscle cells, bardoxolone
      methyl targets multiple cell types relevant to PAH, including endothelial cells, smooth
      muscle cells, and macrophages.

      This is a two-part study.

      Part 1: Part 1 of the study will include both dose-escalation and expansion cohorts.

      Part 2 (extension period):  All patients from Part 1 who complete the 16-week treatment
      period as planned will be eligible to continue directly into the extension period to
      evaluate the intermediate and long-term safety and efficacy of bardoxolone methyl.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in 6-Minute Walk Distance (6MWD)</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Dose 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bardoxolone methyl [Dose 1] mg capsules or placebo by mouth once daily x 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Dose 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bardoxolone methyl [Dose 2] mg capsules or placebo by mouth once daily x 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Dose 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bardoxolone methyl [Dose 3] mg capsules or placebo by mouth once daily x 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Dose 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bardoxolone methyl [Dose 4] mg capsules or placebo by mouth once daily x 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Dose 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bardoxolone methyl [Dose 5] mg capsules or placebo by mouth once daily x 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone methyl</intervention_name>
    <arm_group_label>Cohort 1: Dose 1</arm_group_label>
    <arm_group_label>Cohort 2: Dose 2</arm_group_label>
    <arm_group_label>Cohort 3: Dose 3</arm_group_label>
    <arm_group_label>Cohort 4: Dose 4</arm_group_label>
    <arm_group_label>Cohort 5: Dose 5</arm_group_label>
    <other_name>RTA 402 capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort 1: Dose 1</arm_group_label>
    <arm_group_label>Cohort 2: Dose 2</arm_group_label>
    <arm_group_label>Cohort 3: Dose 3</arm_group_label>
    <arm_group_label>Cohort 4: Dose 4</arm_group_label>
    <arm_group_label>Cohort 5: Dose 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult male and female patients ≥ 18 to ≤ 75 years of age upon study consent;

          2. Symptomatic pulmonary arterial hypertension WHO/NYHA FC class II and III;

          3. One of the following subtypes of WHO Group 1 PAH:

               1. Idiopathic or heritable PAH;

               2. PAH associated with connective tissue disease;

               3. PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1
                  year following shunt repair;

               4. PAH associated with anorexigens;

               5. PAH associated with human immunodeficiency virus (HIV);

          4. Had a diagnostic right heart catheterization performed and documented within 12
             months prior to Screening that confirmed a diagnosis of PAH

          5. Has been receiving an oral, disease-specific PAH therapy consisting of an endothelin
             receptor antagonist (ERA) and/or a phosphodiesterase type-5 inhibitor (PDE5i). PAH
             therapy must be at a stable dose for at least 90 days prior to Day 1;

          6. Has adequate kidney function defined as an estimated glomerular filtration rate
             (eGFR) ≥ 60 mL/min/1.73 m2 using the Modification of Diet in Renal Disease (MDRD)
             4-variable formula;

        Exclusion Criteria:

          1. Participation in other interventional clinical studies within 30 days prior to Day 1;

          2. Participation in an intensive exercise training program for pulmonary rehabilitation
             within 90 days prior to Screening;

          3. Receiving chronic treatment with a prostacyclin/prostacyclin analogue or riociguat
             within 60 days prior to Day 1. Use of prostacyclin for acute vasodilator testing
             during right heart catheterization is allowed;

          4. Requirement for receipt of intravenous inotropes within 30 days prior to Day 1;

          5. Has uncontrolled systemic hypertension as evidenced by sitting systolic blood
             pressure (BP) &gt; 160 mm Hg or sitting diastolic blood pressure &gt; 100 mm Hg during
             Screening after a period of rest;

          6. Has systolic BP &lt; 90 mm Hg during Screening after a period of rest;

          7. Has a history of left-sided heart disease and/or clinically significant cardiac
             disease,including but not limited to any of the following:

               1. Aortic or mitral valve disease (stenosis or regurgitation) defined as greater
                  than mild aortic insufficiency;

               2. Pericardial constriction;

               3. Restrictive or congestive cardiomyopathy;

               4. Left ventricular ejection fraction &lt; 40% at the Screen A echocardiogram (ECHO);

               5. Evidence of left ventricular diastolic dysfunction;

               6. Left ventricular shortening fraction &lt; 22% at the Screen A ECHO;

               7. Symptomatic coronary disease;

          8. Acutely decompensated heart failure within 30 days prior to Day 1, as per
             Investigator assessment;

          9. History of atrial septostomy within 180 days prior to Day 1;

         10. History of obstructive sleep apnea that is untreated;

         11. For patients with HIV-associated PAH, any of the following:

               1. Concomitant active opportunistic infections within 180 days prior to Screening;

               2. Detectable viral load within 90 days prior to Screening;

               3. Cluster designation (CD+) T-cell count &lt; 200 mm3 within 90 days prior to
                  Screening;

               4. Changes in antiretroviral regimen within 90 days prior to Screening;

               5. Using inhaled pentamidine;

         12. Has a history of portal hypertension or chronic liver disease, including hepatitis B
             and/or hepatitis C (with evidence of recent infection and/or active virus
             replication) defined as mild to severe hepatic impairment (Child-Pugh Class A-C);

         13. Serum aminotransferase (ALT or AST) levels &gt; the upper limit of normal (ULN) at
             Screening;
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Harbor - UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>310-222-3560</phone>
    </contact>
    <investigator>
      <last_name>Ronald J. Oudiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cardiac and Vascular Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>720-848-6540</phone>
    </contact>
    <investigator>
      <last_name>David Badesch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Denver Cardiology</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>303-715-2210</phone>
    </contact>
    <investigator>
      <last_name>Ira Dauber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kentuckian Pulmonary Associates</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>502-587-8000</phone>
    </contact>
    <investigator>
      <last_name>John McConnell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>617-636-1334</phone>
    </contact>
    <investigator>
      <last_name>Nicholas Hill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>314-747-8174</phone>
    </contact>
    <investigator>
      <last_name>Murali Chakinala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lindner Center for Research &amp; Education at The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>513-585-1777</phone>
    </contact>
    <investigator>
      <last_name>Peter Engel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <email>roadst@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Jean Elwing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Health Physicians Cincinnati, LLC</name>
      <address>
        <city>Fairfield</city>
        <state>Ohio</state>
        <zip>45014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <email>mdclifford@health-partners.org</email>
    </contact>
    <investigator>
      <last_name>Lynne Wagoner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Legacy Medical Group - Pulmonary Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <email>tmayfiel@lhs.org</email>
    </contact>
    <investigator>
      <last_name>Catherine Markin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Heart Group of Lancaster General Hospital</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <email>LAKruse@lghealth.org</email>
    </contact>
    <investigator>
      <last_name>Justin Roberts, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>214-645-6489</phone>
    </contact>
    <investigator>
      <last_name>Fernando Torres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BreatheAmerica El Paso, Inc.</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>615-665-7130</phone>
    </contact>
    <investigator>
      <last_name>Hernando Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>January 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <keyword>PAH</keyword>
  <keyword>Bardoxolone methyl</keyword>
  <keyword>6-minute walk distance</keyword>
  <keyword>CDDO-me</keyword>
  <keyword>RTA 402</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
